Tony Wood übernimmt im August 2022 die volle Verantwortung für die F&E von GSK Hal Barron wechselt im August 2022 vom CSO zu einem GSK Non-Executive Director mit zusätzlichen Verantwortlichkeiten zur Unterstützung von Forschung und Entwicklung (PRESSEMITTEILUNG) LONDON, 19-Jan-2022 — … Read the full press release
Posted in Healthcare, Management, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged Academy of Medical Sciences, Adrestia, Altius Institute, Altos Labs, biotechnologie, Blenrep, Board of the Rosalind Franklin Institute, Cabenuva, Chief Scientific Officer, CSO, Dr. Hal Barron, Emma Walmsley, Ernennung, F&E, Forschung und Entwicklung, Genome Research, Genomik, GlaxoSmithKline plc, GSK, Immunologie, Imperial College, Infektionskrankheiten, Jemperli, künstliche Intelligenz, maschinelles Lernen, Medikamente, Nucala, Onkologie, Pfizer, Royal Society of Biology, Royal Society of Chemistry, Tony Wood, UK National Genomics Board, University of Newcastle, Xevudy
Tony Wood to assume full accountability for GSK R&D in August 2022 Hal Barron to transition in August 2022 from CSO to a GSK Non-Executive Director with additional responsibilities to support R&D (PRESS RELEASE) LONDON, 19-Jan-2022 — /EuropaWire/ — GlaxoSmithKline … Read the full press release
Posted in Artificial Intelligence (AI), Healthcare, Management, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged Academy of Medical Sciences, Adrestia, Altius Institute, Altos Labs, appointment, artificial-intelligence, biotechnology, Blenrep, Board of the Rosalind Franklin Institute, Cabenuva, Chief Scientific Officer, CSO, Dr. Hal Barron, Emma Walmsley, Genome Research, genomics, GlaxoSmithKline plc, GSK, immunology, Imperial College, infectious disease, Jemperli, Machine Learning, medicines, Nucala®, oncology, Pfizer, R&D, research and development, Royal Society of Biology, Royal Society of Chemistry, Tony Wood, UK National Genomics Board, University of Newcastle, Xevudy
Brentford, UK, 05-Jun-2018 — /EuropaWire/ — GlaxoSmithKline plc (LSE/NYSE: GSK) today announces that it has completed the buyout of Novartis’ 36.5% stake in its Consumer Healthcare Joint Venture for $13 billion (£9.3 billion*). The transaction, which was previously announced on 27 … Read the full press release
Posted in Business, Healthcare, Investment, Pharma & Biotech, United Kingdom
Tagged buyout, Consumer HealthCare, GlaxoSmithKline plc, Healthcare, Novartis, shareholders
GlaxoSmithKline plc (LSE/NYSE: GSK) today announced it is divesting its meningitis vaccines Nimenrix and Mencevax to Pfizer Ireland Pharmaceuticals (a subsidiary of Pfizer Inc). LONDON, 24-6-2015 — /EuropaWire/ — The sale follows commitments given to the European Commission and other … Read the full press release
Marks GSK’s fourth Breakthrough Therapy designation London, UK, 17-1-2014 — /EuropaWire/ — GlaxoSmithKline plc (LSE: GSK) announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for Tafinlar®(dabrafenib) for treatment of patients with metastatic BRAF V600E … Read the full press release
London, UK, 23-10-2013 — /EuropaWire/ — GlaxoSmithKline plc (LSE:GSK) today announced the submission of a New Drug Application (NDA) in the US for the once daily inhaled corticosteroid (ICS) treatment, fluticasone furoate (FF), administered using the ELLIPTA™ dry powder inhaler. The NDA … Read the full press release
Posted in Government, Healthcare, Pharma & Biotech, Science, United Kingdom
Tagged asthma, Bradd Pavur, Catherine Hartley, David Daley, David Mawdsley, ELLIPTA™, ELLIPTA™ dry powder inhaler, fluticasone furoate (FF), fluticasone furoate monotherapy, Gary Davies, GlaxoSmithKline, GlaxoSmithKline plc, GSK, James Dodwell, Jeff McLaughlin, Juan Carlos Molina, Karen Collins, Kirsty Collins (SRI & CG), LSE:GSK, Lucy Singah, Melinda Stubbee, NDA, New Drug Application (NDA), once daily inhaled corticosteroid (ICS) treatment, Simon Steel, Stephen Rea, Tom Curry, US FDA, US regulatory submission, Ziba Shamsi
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions.
HOW TO GET STARTED?